ChemicalBook >> CAS DataBase List >>PD173955

PD173955

CAS No.
260415-63-2
Chemical Name:
PD173955
Synonyms
CS-1508;PD-173955;CHEBI:49791;PD173955 USP/EP/BP;PD173955; CHEBI:49791; 260415-63-2; PD-173955;6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidin-7-one;6-(2,6-Dichlorophenyl)-8-methyl-2-((3-(methylthio)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-on;6-(2,6-Dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one;Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]-;6-(2,6-Dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one PD-173955
CBNumber:
CB82485076
Molecular Formula:
C21H16Cl2N4OS
Molecular Weight:
443.35
MDL Number:
MFCD16038305
MOL File:
260415-63-2.mol
MSDS File:
SDS
Last updated:2023-09-04 15:51:00

PD173955 Properties

Density 1.49
storage temp. Store at -20° C
solubility ≥22.15 mg/mL in DMSO with gentle warming
form White powder.

PD173955 price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ApexBio Technology A8812 PD173955 260415-63-2 1unit $28 2021-12-16 Buy
ApexBio Technology A8812 PD173955 260415-63-2 5mg $138 2021-12-16 Buy
Adipogen Life Sciences SYN-1061-M005 PD-173955 ≥95% 260415-63-2 5mg $297 2021-12-16 Buy
American Custom Chemicals Corporation BRS0000356 PD-173955 95.00% 260415-63-2 1MG $308.7 2021-12-16 Buy
ChemScene CS-3550 PD173955 98.88% 260415-63-2 10mg $336 2021-12-16 Buy
Product number Packaging Price Buy
A8812 1unit $28 Buy
A8812 5mg $138 Buy
SYN-1061-M005 5mg $297 Buy
BRS0000356 1MG $308.7 Buy
CS-3550 10mg $336 Buy

PD173955 Chemical Properties,Uses,Production

Definition

ChEBI: PD173955 is a dichlorobenzene, a methyl sulfide, a pyridopyrimidine and an aryl sulfide. It has a role as a tyrosine kinase inhibitor.

Biological Activity

pd173955 is a potent inhibitor of bcr-abl, src and yes with ic50 value of 1-2 nm, 300 nm and 175 nm, respectively [1-3].bcr-abl is a protein tyrosine kinase which has oncogenic potential. src is an enzyme and plays an important role in a variety of cancer cells survival, angiogenesis, proliferation and invasion pathways. yes is a proto-oncogene tyrosine-protein kinase smf belongs to the src kinase family [1-3].pd173955 is a potent bcr-abl, src and yes inhibitor. when tested with cml cd34+ gm progenitors, pd173955 inhibited kl-dependent proliferation at an ic50 value of 50 nm and gm-csf-dependent cell growth at an ic50 value of 1μm and the maximum inhibition was achieved at the dose of 25 nm. it was shown that pd173955 reduced the fractions of cells in g2-m phase and increased the cells in g1 phase with significant difference [2]. in ht29 cells, pd173955 treatment inhibited src auot-phosphorylation in a dose dependent manner. further, pd173955 showed inhibition on cell growth with ic50 value of 800 nm without morphologic changes and high concentrations arrested cell cycle at the m phase [1]. when tested with bcr-abl-depedent cell lines k562 and rwleu4, pd173955 showed inhibition on cell proliferation with the ic50 value of 35 and 10 nm, respectively and arrested cell cycle in g1 phase at the low nanomolar [3].

Enzyme inhibitor

This tyrosine kinase inhibitor (FW = 443.35 g/mol; CAS 260415-63-2; Solubility: <1 mg/mL DMSO, Ethanol, H2O), 6-(2,6-dichlorophenyl)-8- methyl-2-((3-(methylthio)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one targets Bcr-Abl (IC50 = 1-2 nM, in vitro), the constitutively active tyrosine kinase that results from inadvertent fusion of bcr and abl genes and that causes oncogenic transformation in chronic myelogenous leukemia, or CML, inhibiting Bcr-Abl-dependent cell growth with an IC50 of 2-35 nM in different cell lines. PD173955 also inhibits kit ligand-dependent c-kit autophosphorylation (IC50 = ~25 nM) and kit ligand-dependent proliferation of M07e cells (IC50 = 40 nM), but had a lesser effect on interleukin 3- dependent (IC50 = 250 nM) or granulocyte macrophage colony-stimulating factor (IC50 = 1 μM)-dependent cell growth. PD173955 also increases the susceptibility of HT29 cells to detachment-induced apoptosis (anoikis) in a dose- and time-dependent manner. Structural Features Distinguishing Imatinib & PD173955 Binding: Crystal structures of Abl kinase domain complexes with imatinib (Gleevec) and PD173955 show that both bind to the canonical ATP-binding site, but in distinctive ways. Imatinib captures a specific inactive conformation of Abl’s activation loop, mimicking the bound peptide substrate. In contrast, PD173955 binds to the Abl activation loop in a way that resembles the active kinase conformation. The 10x greater potency of PD173955 over imatinib is attributed to its ability to target multiple active and inactive forms of Abl, whereas imatinib binds only to a specific catalytically inactive conformation (4

References

[1]. windham, t.c., et al., src activation regulates anoikis in human colon tumor cell lines. oncogene, 2002. 21(51): p. 7797-807.
[2]. strife, a., et al., direct evidence that bcr-abl tyrosine kinase activity disrupts normal synergistic interactions between kit ligand and cytokines in primary primitive progenitor cells. mol cancer res, 2003. 1(3): p. 176-85.
[3]. wisniewski, d., et al., characterization of potent inhibitors of the bcr-abl and the c-kit receptor tyrosine kinases. cancer res, 2002. 62(15): p. 4244-55.

PD173955 Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 94)Suppliers
Supplier Tel Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806 sales@capotchem.com China 29797 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32480 60
Hubei Jusheng Technology Co.,Ltd.
18871490254 linda@hubeijusheng.com CHINA 28180 58
BOC Sciences
+1-631-485-4226 inquiry@bocsci.com United States 19553 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427 sales@conier.com China 49390 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250 1026@dideu.com China 29220 58
Hefei Hirisun Pharmatech Co., Ltd
+8615056975894 shawn@hirisunpharm.com CHINA 9923 58
InvivoChem
+1-708-310-1919 +1-13798911105 sales@invivochem.cn United States 6393 58
LEAP CHEM CO., LTD.
+86-852-30606658 market18@leapchem.com China 24738 58
TargetMol Chemicals Inc.
+1-781-999-5354 support@targetmol.com United States 19973 58

PD173955 Spectrum

PD-173955 6-(2,6-Dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one PD-173955 6-(2,6-Dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one 6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidin-7-one 6-(2,6-Dichlorophenyl)-8-methyl-2-((3-(methylthio)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-on CHEBI:49791 PD173955; CHEBI:49791; 260415-63-2; PD-173955 CS-1508 Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- PD173955 USP/EP/BP 260415-63-2 Inhibitors